A. 5 Pharmaceutical aspects

a. Define shelf life and outline factors that may influence drug potency during storage.

The period over which a drug loses 10% of its potency or its guarantee of sterility when stored according to the manufacturer's specifications.

b. Describe methods of preserving shelf-life of drugs

Suitable method depends on the nature of the reactions which would degrade the drug.

```
physical
      sealed containers
      temperature
             refrigeration or freezing to reduce the rate of degrading reactions
             e.g. sux, atracurium, blood products
      light
             dark or opaque containers minimize light-induced changes
             e.g. halothane, nitroprusside
      drving
             dried to powder to reduce reaction rates
             e.g. thio, vec, many antibiotics
chemical
      controlled pH
             many drugs in solution have NaOH or HCl and buffer added
      reducing or oxidizing agents in solution
             usually reducing agents, may cause reactions (e.g. sulfites, nitrites)
      reaction with or adsorption to a carrier
             sugar glasses in phase IIb trials for \alpha_1-antitrypsin
      controlled atmosphere (N_2) or vacuum
             thio, some antibiotics
microbiological
      pretreatment to sterilize drug
             heat, radiation, ethylene oxide
      risk of contamination minimized by physical and chemical methods which remove
      water (and oxygen)
      anti-microbials
             added to many oral agents
             e.g. alcohol, benzalkonium chloride
```

c. Describe the mechanisms of action and potential toxic effects of buffers, antioxidants, anti-microbials and solubilizing agents added to drugs.

additives buffers commonly NaOH, KOH, HCl used to control pH carbonate buffers in LA solutions, methohexitone, thio... phosphate buffers benzenesulfonic acid in atracurium osmolal agents mannitol in dantrolene, vecuronium glucose in spinal LA solutions stabilizing agents antioxidants Na metabisulphite in catecholamine solutions: neurotoxicity

other agents thymol in halothane prevents light inactivation N_2 atmosphere in thiopentone antimicrobials methylparabens used in multidose vials, cause hypersensitivity methyl- and propyl-hydroxybenzoate in topical and IV solutions benzalkonium chloride in nebulizer solutions benzyl alcohol in some water preparations solubilizing agents lipid solutions Cremaphor EL: polyoxyethylated castor oil, hypersensitivity Intralipid: soybean oil, egg phospholipid, glycerol high omega-6-fa content propylene glycol & alcohols solution e.g. diazepam polyethylene glycol in temazepam gelcaps (phlebitis if injected) propellants chlorofluorocarbons in inhalers may be replaced with other agents e.g. N_2 pharmacokinetic alteration binding agents: protamine in insulin uptake: adrenaline in LA compliance flavouring, colouring etc.

d. Outline the variations in generic nomenclature of commonly used drugs.

Not approved	Approved name	Not approved	Approved name
Not approved acetaminophen albuterol aminoacetic acid aminoacridine amobarbital aneurine anthralin asparaginase azidothymidine calciferol carvomenthenol chlormethin cortisol cromolyn dextrose dibucaine epinephrine ergonovine furosemide glyburide	Approved name paracetamol salbutamol glycine aminacrine amylobarbitone thiamine dithranol colaspase zidovudine ergocalciferol terpineol mustine hydrocortisone cromoglycate glucose cinchocaine adrenaline ergometrine frusemide glibenclamide	Not approved laevulose levarterenol levothyroxine lidocaine meperidine mephobarbital methenamine niacin nitroglycerine norephedrine norepinephrine norethinderone omadine penicillin G penicillin V phytonadione pizotyline propoxyphene pyrilamine tetracaine	Approved name fructose noradrenaline thyroxine lignocaine pethidine methylphenobarbitone hexamine nicotinic acid glyceryl trinitrate phenylpropanolamine noradrenaline norethisterone pyrithione benzylpenicillin phenoxymethylpenicillin phytomenadione pizotifen dextropropoxyphene mepyramine amethocaine
isoprotenerol	isoprenaline	tromethamine	trometamol
-	-		

e. Define isomerism, provide a classification with examples and explain its significance.

Isomers are molecules having the same empirical formula but different structures. Chemical isomers have completely different atom to atom bonds, for example enflurane and isoflurane or edrophonium and ephedrine HCl. Stereoisomers or enantiomers have the same bond arrangements but differ in three-dimensional structure due to the presence of chiral centres (atoms bonded to four different groups) which may exist in two mirror-image arrangements or bonds without rotational freedom such as unsaturated carbon-carbon bonds with the two carbon atoms each bonded to different groups.

Chiral centres are present in all amino-acids and many other organic compounds including sugars. They are usually designed D- or L- or d- or l- or R- or S- or (+) or (-) isomers according to their configuration or effect on the polarization of light. Unsaturated bonds are present in many lipids and other molecules and are designated cis- or transisomers (Z- or E-) according to whether the major functional groups on the carbon atoms involved are on the same or opposite sides.



Many organic compounds include multiple chiral centres (e.g. atracurium) or unsaturated bonds (e.g. retinoic acid), yielding multiple optical isomers. As the isomers are different in three dimensional structure, they often bind with different affinities to receptor sites with specific three-dimensional structure and are degraded by enzymes at different rates.

Examples (optical isomers)

isomers equally active

isomers have slightly different potencies and metabolism, e.g. atracurium, ropivacaine

isomers have different actions, e.g. quinine/quinidine

one isomer is active and drug is administered as a racemic mix, e.g. verapamil makes blood levels misleading (active L-verapamil is cleared more rapidly)

one isomer is active and is administered alone, e.g. 1-DOPA

f. Describe the process by which new drugs are approved for research and clinical use in Australia and outline the phases of human drug trials.

Safety tests in animals/tissue culture

acute toxicity

 LD_{50} in animals (2 species, 2 routes), "no effect" dose subacute toxicity

up to 6 months use in three dose ranges in 2 species

chronic toxicity

1-2 years if prolonged use is planned in humans

specific testing

reproduction, carcinogenesis, mutagenicity (Ames test), investigative toxicology

Human evaluation

phase I

establish dose-effect relationship in healthy volunteers or diseases volunteers not blinded, establishes predictable adverse effects and pharmacokinetics

phase II

small single-blind trials in diseased patients with placebo and positive controls phase III

large, usually multicentre, double-blind or crossover trials

phase IV

on-going surveillance for adverse effects during marketing

Phases I trials often start more than 4 years after initial synthesis and phase III may

not be completed until 8 years after initial synthesis. Some drugs are made available for life-threatening or serious diseases without completion of phase III or even phase II trials, e.g. some antiretrovirals.

Australian approval is distinct from overseas approval and applies similar criteria of safety and efficacy as in the US and UK. PBS listing and approval for hospital pharmacopoeia availability depends on cost-effectiveness as well.

The detection of rare adverse effects requires more subjects than are available in phase III trials. For example, to detect the doubling in incidence of a 1/1000 adverse effect requires 18000 subjects (β =0.20, α =0.05). Thus most rare or unpredictable adverse effects will not be detected prior to marketing.

List the plants from which commonly used drugs are derived.

Claviceps purpurea	ergotamine
Erythroxylon coca	cocaine
Papavertum somniferum	morphine, codeine, thebaine, papaverine etc.
Digitalis purpurea, lantana	digoxin
Rauwolfia serpentina	reserpine
Atropa belladonna	atropine
Hyocyamus niger	hyoscine